Article
Licensed
Unlicensed
Requires Authentication
CYP3A4*1B and NAT2*14 Alleles in a Native African Population
-
Isa Cavaco
Published/Copyright:
June 1, 2005
Abstract
Single nucleotide polymorphisms were examined in the cytochrome 450 3A4 (CYP3A4) and N-acetyltransferase 2 (NAT2) genes, which code for major mediators of the metabolism of a wide variety of therapeutic drugs, as well as xenobiotics. We determined, in a population from Guinea-Bissau, the frequencies of CYP3A4 and NAT2 variants expected to be prevalent among Africans, due to the high frequency previously observed in African Americans. The observed frequencies were 72% for CYP3A4*1B and 19.2% for the NAT2 191 G>A variant. The high frequency found for these potentially function-altering polymorphisms suggests the possibility of impaired metabolism through CYP3A4 and NAT2 in this population. Strikingly, the frequency observed for the NAT2 191 G>A single nucleotide polymorphism (SNP), associated with the slow acetylator phenotype, was significantly higher than found in other African populations, suggesting the existence of a west to east gradient across Sub-Saharan Africa. The prevalence of these variants may be relevant with regard to therapeutic efficacy in African populations for it may potentially affect drug clearance and consequently, increase the incidence of side effects and drug-drug interactions.
:
Published Online: 2005-06-01
Published in Print: 2003-04-25
Copyright © 2003 by Walter de Gruyter GmbH & Co. KG
You are currently not able to access this content.
You are currently not able to access this content.
Articles in the same Issue
- First Santorini Conference: From Genetic Variations to Risk Prediction and Pharmacogenomics
- Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An Overview
- Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy
- The Proteome: Anno Domini 2002
- Cardiac Sodium Channel Diseases
- Haemophilia B: From Molecular Diagnosis to Gene Therapy
- The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics
- Molecular Diagnostics by Microelectronic Microchips
- Molecular Beacons as Diagnostic Tools: Technology and Applications
- Electrochemical DNA Sensor for Detection of Single Nucleotide Polymorphisms
- Comparison of Standard PCR and the LightCycler® Technique to Determine the Thrombophilic Mutations: An Efficiency and Cost Study
- Impact of Purified Water Quality on Molecular Biology Experiments
- Which Are the best Tools for Specific Clinical Application (Chips, Multiplex, Mass Spec Profile, etc.)?
- Genetic Variations Observed in Arterial and Venous Thromboembolism – Relevance for Therapy, Risk Prevention and Prognosis
- The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity
- The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina
- The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects
- Left Ventricular Size, Mass and Function in Relation to Angiotensin-Converting Enzyme Gene and Angiotensin-II Type 1 Receptor Gene Polymorphisms in Patients with Coronary Artery Disease
- Analysis of Multiple Single Nucleotide Polymorphisms of Candidate Genes Related to Coronary Heart Disease Susceptibility by Using Support Vector Machines
- PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study
- Lipoprotein Lipase Gene Polymorphisms in Croatian Patients with Coronary Artery Disease
- Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism and the B-Vitamins: A Facet of Nature-Nurture Interplay
- Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?
- Ethical Issues: Should We Give the Predictive Genetic Profile to the Citizens?
- Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems
- Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine
- Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
- Pharmacogenomics of Drugs Affecting the Cardiovascular System
- Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidence
- CYP3A4*1B and NAT2*14 Alleles in a Native African Population
- Pharmacogenetics: From Bench to Bedside
- Meetings and Awards
Articles in the same Issue
- First Santorini Conference: From Genetic Variations to Risk Prediction and Pharmacogenomics
- Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An Overview
- Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy
- The Proteome: Anno Domini 2002
- Cardiac Sodium Channel Diseases
- Haemophilia B: From Molecular Diagnosis to Gene Therapy
- The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics
- Molecular Diagnostics by Microelectronic Microchips
- Molecular Beacons as Diagnostic Tools: Technology and Applications
- Electrochemical DNA Sensor for Detection of Single Nucleotide Polymorphisms
- Comparison of Standard PCR and the LightCycler® Technique to Determine the Thrombophilic Mutations: An Efficiency and Cost Study
- Impact of Purified Water Quality on Molecular Biology Experiments
- Which Are the best Tools for Specific Clinical Application (Chips, Multiplex, Mass Spec Profile, etc.)?
- Genetic Variations Observed in Arterial and Venous Thromboembolism – Relevance for Therapy, Risk Prevention and Prognosis
- The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity
- The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina
- The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects
- Left Ventricular Size, Mass and Function in Relation to Angiotensin-Converting Enzyme Gene and Angiotensin-II Type 1 Receptor Gene Polymorphisms in Patients with Coronary Artery Disease
- Analysis of Multiple Single Nucleotide Polymorphisms of Candidate Genes Related to Coronary Heart Disease Susceptibility by Using Support Vector Machines
- PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study
- Lipoprotein Lipase Gene Polymorphisms in Croatian Patients with Coronary Artery Disease
- Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism and the B-Vitamins: A Facet of Nature-Nurture Interplay
- Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?
- Ethical Issues: Should We Give the Predictive Genetic Profile to the Citizens?
- Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems
- Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine
- Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
- Pharmacogenomics of Drugs Affecting the Cardiovascular System
- Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidence
- CYP3A4*1B and NAT2*14 Alleles in a Native African Population
- Pharmacogenetics: From Bench to Bedside
- Meetings and Awards
